Granted Patent
B2
US 12,492,375 · App. 15/930,571 · Granted Dec 9, 2025
T-cell receptor-deficient T cell compositions
Assignee:
THE TRUSTEES OF DARTMOUTH COLLEGE
C12N5/0636A61K35/17A61K39/0011A61K40/11A61K40/32A61K40/4224A61K2035/124A61K2039/5156A61K2039/585A61K2239/31A61K2239/38A61K2239/48A61K2239/59C12N2501/515C12N2510/02C12N2511/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
Claims (11)
1 . A method of treating an infection or infectious condition in a human subject in need thereof which comprises administering a therapeutically effective amount of a composition comprising a recombinant human T cell or progeny thereof, which human T cell or progeny thereof (i) has been modified to reduce expression of the endogenous T cell receptor (TCR), and (ii) has been further modified to express at least one pathogen-associated receptor which binds to an antigen expressed by the pathogen which causes the infection or infectious condition, and wherein said pathogen-associated receptor is attached to at least one signaling domain.
2 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a virus.
3 . The method of claim 1 , wherein in (i) the modification of the endogenous TCR results in reduced expression of the TCR alpha subunit and/or TCR beta subunit.
4 . The method of claim 1 , wherein in (i) the modification of the endogenous TCR results in reduced expression of the TCR beta subunit.
5 . The method of claim 1 , wherein in (i) the modification of the endogenous TCR results in reduced expression of the TCR alpha and beta subunits.
6 . The method of claim 1 , wherein in (i) the modification of the endogenous TCR results in reduced expression of the TCR alpha subunit.
7 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a bacterium.
8 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a fungus.
9 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a yeast.
10 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a protozoan.
11 . The method of claim 1 , wherein the pathogen which causes the infection or infectious condition is a parasite.
Continuity (6)
Division
15815197
· Nov 16, 2017
Division
15383662
· Dec 19, 2016
Division
13502978
Provisional Application
61255980
· Oct 29, 2009
References Cited (400)
US 5415874A
· Bender et al.
· 1995
[cited by applicant]
US 5552300A
· Makrides et al.
· 1996
[cited by applicant]
US 5667967A
· Steinman et al.
· 1997
[cited by applicant]
US 5686281A
· Roberts
· 1997
[cited by applicant]
US 5830755A
· Nishimura et al.
· 1998
[cited by applicant]
US 5851828A
· Seed et al.
· 1998
[cited by applicant]
US 6103521A
· Capon et al.
· 2000
[cited by applicant]
US 6133433A
· Hema et al.
· 2000
[cited by applicant]
US 6190656B1
· Clifford et al.
· 2001
[cited by applicant]
US 6242567B1
· Hema et al.
· 2001
[cited by applicant]
US 6284240B1
· Seed et al.
· 2001
[cited by applicant]
US 6407221B1
· Capon et al.
· 2002
[cited by applicant]
US 6410319B1
· Raubitschek et al.
· 2002
[cited by applicant]
US 6464978B1
· Brostoff et al.
· 2002
[cited by applicant]
US 6753162B1
· Seed et al.
· 2004
[cited by applicant]
US 6770749B2
· Ellenhorn et al.
· 2004
[cited by applicant]
US 6984382B1
· Groner et al.
· 2006
[cited by applicant]
US 7049136B2
· Seed et al.
· 2006
[cited by applicant]
US 7052906B1
· Lawson et al.
· 2006
[cited by applicant]
US 7070995B2
· Jensen
· 2006
[cited by applicant]
US 7094599B2
· Seed et al.
· 2006
[cited by applicant]
US 7435596B2
· Campana et al.
· 2008
[cited by applicant]
US 7446179B2
· Jensen et al.
· 2008
[cited by applicant]
US 7446190B2
· Sadelain et al.
· 2008
[cited by applicant]
US 7456263B2
· Sherman et al.
· 2008
[cited by applicant]
US 7514537B2
· Jensen
· 2009
[cited by applicant]
US 7569357B2
· Kranz et al.
· 2009
[cited by applicant]
US 7608410B2
· Dunn et al.
· 2009
[cited by applicant]
US 7618817B2
· Campbell
· 2009
[cited by applicant]
US 7655461B2
· Finn et al.
· 2010
[cited by applicant]
US 7763243B2
· Lum et al.
· 2010
[cited by applicant]
US 7820174B2
· Wang et al.
· 2010
[cited by applicant]
US 7994298B2
· Zhang et al.
· 2011
[cited by applicant]
US 8026097B2
· Campana et al.
· 2011
[cited by applicant]
US 8252914B2
· Zhang et al.
· 2012
[cited by applicant]
US 8283446B2
· Jakobsen et al.
· 2012
[cited by applicant]
US 8399645B2
· Campana et al.
· 2013
[cited by applicant]
US 8465743B2
· Rosenberg et al.
· 2013
[cited by applicant]
US 8519100B2
· Jakobsen et al.
· 2013
[cited by applicant]
US 8835617B2
· Luban et al.
· 2014
[cited by applicant]
US 8945868B2
· Collingwood et al.
· 2015
[cited by applicant]
US 8956828B2
· Bonini et al.
· 2015
[cited by applicant]
US 9051391B2
· Mineno et al.
· 2015
[cited by applicant]
US 9273283B2
· Sentman et al.
· 2016
[cited by applicant]
US 9663763B2
· Sentman et al.
· 2017
[cited by applicant]
US 9821011B1
· Sentman et al.
· 2017
[cited by applicant]
US 9938497B2
· Sentman et al.
· 2018
[cited by applicant]
US 9957480B2
· Sentman et al.
· 2018
[cited by applicant]
US 20010007152A1
· Sherman et al.
· 2001
[cited by applicant]
US 20020045241A1
· Schendel
· 2002
[cited by applicant]
US 20030060444A1
· Finney et al.
· 2003
[cited by applicant]
US 20030077249A1
· Bebbington et al.
· 2003
[cited by applicant]
US 20030082719A1
· Schumacher et al.
· 2003
[cited by applicant]
US 20030093818A1
· Belmont et al.
· 2003
[cited by applicant]
US 20030219463A1
· Falkenburg et al.
· 2003
[cited by applicant]
US 20040038886A1
· Finney et al.
· 2004
[cited by applicant]
US 20040115198A1
· Spies et al.
· 2004
[cited by applicant]
US 20040259196A1
· Zipori et al.
· 2004
[cited by applicant]
US 20050048055A1
· Newell et al.
· 2005
[cited by applicant]
US 20050113564A1
· Campana et al.
· 2005
[cited by applicant]
US 20050129671A1
· Cooper et al.
· 2005
[cited by applicant]
US 20050238626A1
· Yang et al.
· 2005
[cited by applicant]
US 20060247420A1
· Coukos et al.
· 2006
[cited by applicant]
US 20060269529A1
· Niederman et al.
· 2006
[cited by applicant]
US 20070066802A1
· Geiger
· 2007
[cited by applicant]
US 20070077241A1
· Spies et al.
· 2007
[cited by applicant]
US 20090202501A1
· Zhang et al.
· 2009
[cited by applicant]
US 20090214533A1
· Clynes
· 2009
[cited by examiner]
US 20090226404A1
· Schuler et al.
· 2009
[cited by applicant]
US 20090304657A1
· Morgan et al.
· 2009
[cited by applicant]
US 20100009863A1
· Himmler et al.
· 2010
[cited by applicant]
US 20100105136A1
· Carter et al.
· 2010
[cited by applicant]
US 20100135974A1
· Eshhar et al.
· 2010
[cited by applicant]
US 20110213288A1
· Choi et al.
· 2011
[cited by applicant]
US 20120015434A1
· Campana et al.
· 2012
[cited by applicant]
US 20120294857A1
· Sentman et al.
· 2012
[cited by applicant]
US 20130216509A1
· Campana et al.
· 2013
[cited by applicant]
US 20130266551A1
· Campana et al.
· 2013
[cited by applicant]
US 20130323214A1
· Gottschalk et al.
· 2013
[cited by applicant]
DE 4408999
· 1995
[cited by applicant]
DE 19540515
· 1997
[cited by applicant]
DE 10259713
· 2004
[cited by applicant]
EP 0340793
· 1995
[cited by applicant]
EP 0499555
· 2000
[cited by applicant]
EP 0574512
· 2003
[cited by applicant]
EP 1226244
· 2004
[cited by applicant]
EP 0871495
· 2005
[cited by applicant]
EP 1075517
· 2006
[cited by applicant]
EP 1932537
· 2008
[cited by applicant]
EP 1765860
· 2008
[cited by applicant]
EP 2186825
· 2010
[cited by applicant]
EP 1791865
· 2010
[cited by applicant]
JP H05176760
· 1993
[cited by applicant]
JP 11243955
· 1999
[cited by applicant]
JP 2008523783
· 2008
[cited by applicant]
JP 2011512786
· 2011
[cited by applicant]
WO WO1991018019
· 1991
[cited by applicant]
WO WO1992015322
· 1992
[cited by applicant]
WO WO1994024282
· 1994
[cited by applicant]
WO WO1996015238
· 1996
[cited by applicant]
WO WO1996013584
· 1996
[cited by applicant]
WO WO1998018809
· 1998
[cited by applicant]
WO WO1998041613
· 1998
[cited by applicant]
WO WO2000031239
· 2000
[cited by applicant]
WO WO2000014257
· 2000
[cited by applicant]
WO WO2001092291
· 2001
[cited by applicant]
WO WO2004056845
· 2004
[cited by applicant]
WO 2005044996
· 2005
[cited by applicant]
WO 2006036445
· 2006
[cited by applicant]
WO WO2006103429
· 2006
[cited by applicant]
WO WO2006060878
· 2006
[cited by applicant]
WO 2008153029
· 2008
[cited by applicant]
WO WO2009059804
· 2009
[cited by applicant]
WO WO2009091826
· 2009
[cited by applicant]
WO WO2010012829
· 2010
[cited by applicant]
WO WO2010025177
· 2010
[cited by applicant]
WO WO2010058023
· 2010
[cited by applicant]
WO WO2010088160
· 2010
[cited by applicant]
WO WO2010037395
· 2010
[cited by applicant]
WO WO2010107400
· 2010
[cited by applicant]
WO WO2011059836
· 2011
[cited by applicant]
WO 2011070443
· 2011
[cited by applicant]
WO WO2012050374
· 2012
[cited by applicant]
WO WO2013166051
· 2013
[cited by applicant]
Ito et al. (Journal of Virology, Feb. 2001, p. 1576-1580). (Year: 2001).
[cited by examiner]
Hoenen et al. (Trends in Molecular Medicine, vol. 12, Issue 5, 2006, pp. 206-215). (Year: 2006).
[cited by examiner]
Ryan et al., Chapter 4 “Middle Ear Molecular Biology” of the book Clinical Ontology, 3rd Ed., 2007, pp. 55-65, by Hughes et al., Thieme. (Year: 2007).
[cited by examiner]
Paulos et al. (Clin Cancer Res 2007;13(18), pp. 5280-5289). (Year: 2007).
[cited by examiner]
Hoelzer et al. (Nucleic Acids Res. May 2008; 36(9): 2825-2837). (Year: 2008).
[cited by examiner]
Jensen, M C et al. “Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.” Cytotherapy vol. 5,2 (2003): 131-8. doi:10.1080/14653240310001028.
[cited by applicant]
“Viral Antigens.” ProSpec Protein Specialists. Web. Sep. 10, 2010. < http://www.prospecbio.com/Viral_Antigens/>. Internet Archive. <https://web.archive.org/web/20100910230148/http://www.prospecbio.com:80/Viral_Antigens/…
[cited by applicant]
“Products & Ordering—Recombinant Proteins.” Jena Bioscience. Web. Sep. 2, 2010. <http://www.jenabioscience.com/cms/en/1/browse/110_recombinant_proteins.html>. Internet Archive. <https://web.archive.org/web/2010090205065…
[cited by applicant]
Liu L, et al. “Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors,” Cancer Lett. Mar. 2012;316(1):1-5.
[cited by applicant]
Nagorsen D, et al. “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. May 15, 2011;317(9):1255-60.
[cited by applicant]
Marín R, et al. “Analysis of HLA-E expression in human tumors,” Immunogenetics. Feb. 2003;54(11):767-75.
[cited by applicant]
Palmisano GL, et al. “HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines,” Hum Immunol. Jan. 2005;66(1):1-12.
[cited by applicant]
Alajez NM ‘MHC-Unrestricted MUC1-Specific T Cell Receptor for Cancer Immunotherapy/Gene Therapy’ (2003) MHC-Unrestricted MUC1-Specific T Cell Receptor For Cancer Immunotherapy/Gene Therapy. Doctoral Dissertation, Univer…
[cited by applicant]
Alajez NM, et al. ‘Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of theinnate and the adaptive immune system through bone marrow transduction and immune reconsti…
[cited by applicant]
Alli R, et al. ‘Retrogenic Modeling of Experimental Allergic Encephalomyelitis Associates T Cell Frequency but Not TCR Functional Affinity with Pathogenicity’ J Immunol. Jul. 1, 2008;181(1):136-45.
[cited by applicant]
Almåsbak H, et al. ‘Non-MHC-dependent redirected T cells against tumor cells.’ Methods Mol Biol. 2010;629:453-93. doi: 10.1007/978-1-60761-657-3_28.
[cited by applicant]
Beecham EJ, et al. ‘Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.’ J Immunother. May-Jun. 2000;23(3):332-43.
[cited by applicant]
Bell LM, et al. ‘Cytoplasmic tail deletion of T cell receptor (TCR) beta-chain results in its surface expression as glycosylphosphatidylinositol-anchored polypeptide on mature T cells in the absence of TCR-alpha.’ J Bio…
[cited by applicant]
Berry LJ, et al. ‘Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.’ Tissue Antigens. Oct. 2009;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x.
[cited by applicant]
Bialer G, et al. ‘Selected murine residues endow human TCR with enhanced tumor recognition’ J Immunol. Jun. 1, 2010;184(11):6232-41. doi: 10.4049/jimmunol.0902047. Epub Apr. 28, 2010.
[cited by applicant]
Billadeau DD, et al. ‘NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.’ Nat Immunol. Jun. 2003;4(6):557-64. Epub May 11, 2003.
[cited by applicant]
Bridgeman JS, et al. ‘The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.’ J Immunol…
[cited by applicant]
Chmielewski M, et al. ‘CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack.’ Gene Ther. Jan. 2011;18(1):62-72. doi: 10.1038/gt.2010.127. Epub Oct. 14, 2010.
[cited by applicant]
Cohen CJ, et al. ‘Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes is Associated with Improved Pairing and TCR/CD3 Stability’ Cancer Res. Sep. 1, 2006;66(17):8878-86.
[cited by applicant]
Cooper LJ, et al. ‘Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.’ Cytotherapy. 2006;8(2):105-17.
[cited by applicant]
Dall P, et al. ‘In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cell’ Cancer Immunol Immunother. Jan. 2005;54(1):51-60.
[cited by applicant]
Danielian S, et al. ‘Both T cell receptor (TcR)-CD3 complex and CD2 increase the tyrosine kinase activity of p56lck. CD2 can mediate TcR-CD3-independent and CD45-dependent activation of p56lck.’ Eur J Immunol. Nov. 1992…
[cited by applicant]
Donnadieu et al., ‘Reconstitution of CD3 zeta coupling to calcium mobilization via genetic complementation.’ J Biol. Chem. 269:32828-34 (1994).
[cited by applicant]
Dennehy KM, et al. ‘Mitogenic CD28 Signals Require the Exchange Factor Vav1 to Enhance TCR Signaling at the SLP-76-Vav-Itk Signalosome’ J Immunol. Feb. 1, 2007;178(3):1363-71.
[cited by applicant]
D'Oro U, et al. ‘Regulation of constitutive TCR internalization by the zeta-chain.’ J Immunol. Dec. 1, 2002;169(11):6269-78.
[cited by applicant]
Duplay P, et al. ‘An activated epidermal growth factor receptor/Lck chimera restores early T cell receptor-mediated calcium response in a CD45-deficient T cell line.’ J Biol Chem. Jul. 26, 1996;271(30):17896-902.
[cited by applicant]
Eshhar Z, et al. ‘Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptor…
[cited by applicant]
Favier B, et al. ‘TCR dynamics on the surface of living T cells’ Int Immunol. Dec. 2001;13(12):1525-32.
[cited by applicant]
Finney HM, et al. ‘Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.’ J Immunol. Sep. 15, 1998;161(6):2791-7.
[cited by applicant]
Frankel TL, et al. ‘Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase’ J Immunol. Jun. 1, 2010;184(11):5988-98. doi: 10.4049/jimmunol.…
[cited by applicant]
Fujihashi K, et al. ‘gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A response’ J Exp Med. Apr. 1, 1996;183(4):1929-35.
[cited by applicant]
Garrity D, et al. ‘The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure.’ Proc Natl Acad Sci U S A. May 24, 2005;102(21):7641-6. Epub May 13, 2005.
[cited by applicant]
Geiger TL, et al. ‘The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes.’ J Immunol. May 15, 1999;162(10):5931-9.
[cited by applicant]
Geiger TL, et al. ‘Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes’ Blood. Oct. 15, 2001;98(8):2364-71.
[cited by applicant]
Gouaillard C, et al. ‘Evolution of T cell receptor (TCR) α β heterodimer assembly with the CD3 complex’ Eur J Immunol. Dec. 2001;31(12):3798-805.
[cited by applicant]
Hawkins RE, et al. ‘Development of adoptive cell therapy for cancer: a clinical perspective.’ Hum Gene Ther. Jun. 2010;21(6):665-72. doi: 10.1089/hum.2010.086.
[cited by applicant]
Haynes NM, et al. ‘Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-ζ vs FcεRI-65 ’ J Immunol. Jan. 1, 2001;166(1):182-7.
[cited by applicant]
Horng T, et al. ‘NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway.’ Nat Immunol. Dec. 2007;8(12):1345-52. Epub Oct. 21, 2007.
[cited by applicant]
Imai C, et al. ‘Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.’ Leukemia. Apr. 2004;18(4):676-84.
[cited by applicant]
Irles C, et al. ‘CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling.’ Nat Immunol. Feb. 2003;4(2):189-97. Epub Dec. 23, 2002.
[cited by applicant]
Itohara S, et al. ‘T cell receptor delta gene mutant mice: independent generation of alpha beta T cells and programmed rearrangements of gamma delta TCR genes.’ Cell. Feb. 12, 1993;72(3):337-48.
[cited by applicant]
Joyce DE, et al. ‘Functional interactions between the thrombin receptor and the T-cell antigen receptor in human T-cell lines’ Blood. Sep. 1, 1997;90(5):1893-901.
[cited by applicant]
Kieback E, et al. ‘Enhanced T cell receptor gene therapy for cancer.’ Expert Opin Biol Ther. May 2010;10(5):749-62. doi: 10.1517/14712591003689998.
[cited by applicant]
Kieback E, et al. ‘A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer’ Proc Natl Acad Sci U S A. Jan. 15, 2008;105(2):623-8. doi: 10.1073/pnas.0710198105. Epub Jan. 8, 2008.
[cited by applicant]
Kreiß et al., ‘Contrasting contributions of complementarity-determining region 2 and hypervariable region 4 of rat BV8S2+ (Vbeta8.2) TCR to the recognition of myelin basic protein and different types of bacterial supera…
[cited by applicant]
Koya RC, et al. ‘Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.’ Proc Natl Acad Sci U S A. Aug. 10, 2010;107(32):14286-91. doi: 10.1073/…
[cited by applicant]
Leisegang M, et al. ‘T-Cell Receptor Gene-Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy’ Clin Cancer Res. Apr. 15, 2010;16(8):2333-43. doi: 10.1158/1078-0432.CCR-09-2897. Epub…
[cited by applicant]
Liang X, et al. ‘A Single TCRα-Chain with Dominant Peptide Recognition in the Allorestricted HER2/neu-Specific T Cell Repertoire’ J Immunol. Feb. 1, 2010;184(3):1617-29. doi: 10.4049/jimmunol.0902155. Epub Dec. 30, 2009.
[cited by applicant]
Lin WY, et al. ‘Developmental dissociation of T cells from B, NK, and myeloid cells revealed by MHC class II-specific chimeric immune receptors bearing TCR-zeta or FcR-gamma chain signaling domains.’ Blood. Oct. 15, 200…
[cited by applicant]
Losch FO, et al. ‘Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain.’ Int J Cancer. Jan. 20, 2003;103(3):399-407.
[cited by applicant]
Maher J, et al. ‘Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.’ Nat Biotechnol. Jan. 2002;20(1):70-5.
[cited by applicant]
Mallevaey T, et al. ‘T Cell Receptor CDR2b and CDR3b Loops Collaborate Functionally to Shape the INKT Cell Repertoire’ Immunity. Jul. 17, 2009;31(1):60-71. doi: 10.1016/j.immuni.2009.05.010.
[cited by applicant]
Marie-Cardine A, et al. ‘SHP2-interacting Transmembrane Adaptor Protein (SIT), A Novel Disulfide-linked Dimer Regulating Human T Cell Activation’ J Exp Med. Apr. 19, 1999;189(8):1181-94.
[cited by applicant]
McFarland HI, et al. ‘Signaling through MHC in transgenic mice generates a population of memory phenotype cytolytic cells that lack TCR.’ Blood. Jun. 1, 2003;101(11):4520-8. Epub Feb. 13, 2003.
[cited by applicant]
Mekala DJ, et al. ‘IL-10-dependent suppression of experimental allergic encephalomyelitis by Th2-differentiated, anti-TCRredirected T lymphocytes.’ J Immunol. Mar. 15, 2005;174(6):3789-97.
[cited by applicant]
Meresse B, et al. ‘Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.’ Immunity. Sep. 2004;21(3):357-66.
[cited by applicant]
Milone MC, et al. ‘Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.’ Mol Ther. Aug. 2009;17(8):1453-64. doi: 10.1038/mt.20…
[cited by applicant]
Mizoguchi A, et al. ‘Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice.’ J Exp Med. Aug. 1, 1996;184(2):707-15.
[cited by applicant]
Moeller M, et al. ‘A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.’ Cancer Gene Ther. May 2004;11(5):371-9.
[cited by applicant]
Moisini I, et al. ‘Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-ζ Chimeric Receptor’ J Immunol. Mar. 1, 2008;180(5):3601-11.
[cited by applicant]
Mombaerts P, et al. ‘Mutations in T-cell antigen receptor genes alpha and beta block thymocyte development at different stages.’ Nature. Nov. 19, 1992;360(6401):225-31.
[cited by applicant]
Motmans K, et al. ‘Enhancing the tumor-specifity of human T cells by the expression of chimericimmunoglobulin/T cell receptor genes.’ Immunotechnology, Nov. 1996;2(4): 303-304(2).
[cited by applicant]
Nguyen P, et al. ‘Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes.’ Gene Ther. Apr. 2003;10(7):594-604.
[cited by applicant]
Nguyen P, et al. ‘Discrete TCR repertoires and CDR3 features distinguish effector and Foxp3+ regulatory T lymphocytes in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis.’ J Immunol. O…
[cited by applicant]
Okamoto et al., ‘Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.’ Cancer Res 69:9003-11 (2009).
[cited by applicant]
Nguyen P, et al. ‘Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function.’ Blood. Dec. 15, 2003;102(13):4320-5. Epub Aug. 28, 2003.
[cited by applicant]
Polic B, et al. ‘How alpha beta T cells deal with induced TCR alpha ablation.’ Proc Natl Acad Sci U S A. Jul. 17, 2001;98(15):8744-9. Epub Jul. 10, 2001.
[cited by applicant]
Qian D, et al. ‘Dominant-negative zeta-associated protein 70 inhibits T cell antigen receptor signaling.’ J Exp Med. Feb. 1, 1996;183(2):611-20.
[cited by applicant]
Rivera A, et al. ‘Host stem cells can selectively reconstitute missing lymphoid lineages in irradiation bone marrow chimeras.’ Blood. Jun. 1, 2003;101(11):4347-54. Epub Feb. 13, 2003.
[cited by applicant]
Rossig C, et al. ‘Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes’ Int J Cancer. Oct. 15, 2001;94(2):228-36.
[cited by applicant]
Sadelain M. ‘T-cell engineering for cancer immunotherapy.’ Cancer J. Nov.-Dec. 2009;15(6):451-5. doi: 10.1097/PPO.0b013e3181c51f37.
[cited by applicant]
Schirrmann T, et al. ‘Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo’ Cancer Gene Ther. Apr. 2002;9(4):390-8.
[cited by applicant]
Schmitt TM, et al. ‘T cell receptor gene therapy for cancer.’ Hum Gene Ther. Nov. 2009;20(11):1240-8. doi: 10.1089/hum.2009.146.
[cited by applicant]
Sommermeyer D, et al. ‘Designer T cells by T cell receptor replacement’ Eur J Immunol. Nov. 2006;36(11):3052-9.
[cited by applicant]
Spaapen R ‘Rebuilding human leukocyte antigen class II-restricted.’ Novel strategies for identification and therapeutic application of minor histocompatibility antigens 13 (2009): 79.
[cited by applicant]
Spaapen R, et al. ‘Rebuilding Human Leukocyte Antigen Class II-Restricted Minor Histocompatibility Antigen Specificity in Recall Antigen-Specific T Cells by Adoptive T Cell Receptor Transfer: Implications for Adoptive I…
[cited by applicant]
Sturmhöfel K, et al. ‘Antigen-independent, integrin-mediated T cell activation.’ J Immunol. Mar. 1, 1995;154(5):2104-11.
[cited by applicant]
Sugita M, et al. ‘Failure of Trafficking and Antigen Presentation by CD1 in AP-3-Deficient Cells’ Immunity. May 2002;16(5):697-706.
[cited by applicant]
Symes J, et al. ‘Genetic Modification of T Lymphocytes for Cancer Therapy’ Gene Therapy and Cancer Research Focus (2008): 163.
[cited by applicant]
Udyavar A, et al. ‘Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.’ Arch Immunol Ther Exp (Warsz). Oct. 2010;58(5):335-46. doi: 10.1007/s00005-010-0090-1. Epub Aug. 1, 2010.
[cited by applicant]
Udyavar A, et al. ‘Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity’ J Immunol. Apr. 1, 2009;182(7):4439-47. doi: 10.4049/jimmu…
[cited by applicant]
Verneris MR, et al. ‘Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.’ Blood. Apr. 15, 2004;103(8):3065-72. Epub Nov. 20, 2003.
[cited by applicant]
Voss RH, et al. ‘Molecular design of the Cαβ interface favors specific pairing of introduced TCRαβ in human T cells’ J Immunol. Jan. 1, 2008;180(1):391-401.
[cited by applicant]
Wang J, et al. ‘Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.’ Hum Gene Ther. Aug. 2007;18(8):712-25.
[cited by applicant]
Weiss A, et al. ‘Regulation of protein tyrosine kinase activation by the T-cell antigen receptor zeta chain.’ Cold Spring Harb Symp Quant Biol. 1992;57:107-16.
[cited by applicant]
Williams BL, et al. ‘Genetic evidence for differential coupling of Syk family kinases to the T-cell receptor: reconstitution studies in a ZAP-70-deficient Jurkat T-cell line.’ Mol Cell Biol. Mar. 1998;18(3):1388-99.
[cited by applicant]
Wu J, et al. ‘An activating immunoreceptor complex formed by NKG2D and DAP10.’ Science. Jul. 30, 1999;285(5428):730-2.
[cited by applicant]
Xu H, et al. ‘A kinase-independent function of Lck in potentiating antigen-specific T cell activation.’ Cell. Aug. 27, 1993;74(4):633-43.
[cited by applicant]
Yachi PP, et al. ‘Altered Peptide Ligands Induce Delayed CD8-T Cell Receptor Interaction—a Role for CD8 in Distinguishing Antigen Quality’ Immunity. Aug. 2006;25(2):203-11. Epub Jul. 27, 2006.
[cited by applicant]
Zhang T, et al. ‘Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.’ Cancer Res. Jun. 1, 2006;66(11):5927-33.
[cited by applicant]
Zhao Y, et al. ‘A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity’ J Immunol. Nov. 1, 2009;183(9):5563-74. doi: 10.…
[cited by applicant]
Yu C, et al. ‘Inhibitory signaling potential of a TCR-like molecule in lamprey.’ Eur J Immunol. Feb. 2009;39(2):571-9. doi: 10.1002/eji.200838846.
[cited by applicant]
Lustgarten J, et al. Specific elimination of IgE production using T cell lines expressing chimeric T cell receptor genes, Eur J Immunol. Oct. 1995;25(10):2985-91.
[cited by applicant]
Surh CD, et al. “Homeostasis of memory T cells,” Immunol Rev. Jun. 2006;211:154-63.
[cited by applicant]
Schneider MA, et al. “CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells,” J Exp Med. Apr. 16, 2007;204(4):735-45.
[cited by applicant]
Maloy KJ, et al. “Fueling regulation: IL-2 keeps CD4+ Treg cells fit,” Nat Immunol. Nov. 2005;6(11):1071-2.
[cited by applicant]
Call ME, et al. “Molecular mechanisms for the assembly of the T cell receptor-CD3 complex,” Mol Immunol. Apr. 2004;40(18):1295-305.
[cited by applicant]
Cooper TA. “Use of minigene systems to dissect alternative splicing elements,” Methods. Dec. 2005;37(4):331-40.
[cited by applicant]
Ehlers S, et al. “Alphabeta T cell receptor-positive cells and interferon-gamma, but not inducible nitric oxide synthase, are critical for granuloma necrosis in a mouse model of mycobacteria-induced pulmonary immunopath…
[cited by applicant]
Madrenas, J. et al., “Thymus-independent Expression of Truncated T Cell Receptor—a mRNA in Murine Kidney,” The Journal of Immunology, vol. 148, No. 2, pp. 612-619, Jan. 15, 1992. Abstract.
[cited by applicant]
Roberts, S. et al., “T-Cell a˜+ and yo+ Deficient Mice Display Abnormal but Distinct Phenotypes Toward a Natural, Widespread Infection of the Intestinal Epithelium,” PNAS, Oct. 1996, vol. 93, pp. 11174-11779.
[cited by applicant]
Stoss et al., Brian Research Protocols 4 (1999).383-394.
[cited by applicant]
Szczepanik, M. et al., “Gamma.delta. T Cells from Tolerized a˜ T Cell Receptor (TCR)-deficient Mice Inhibit Contact Sensitivity-effector T Cells in Vivo, and Their Interferon-γ Production in Vitro,” The Journal of Exper…
[cited by applicant]
Trickett et al., Journal of Immunological Methods 275 (2003) 251-255.
[cited by applicant]
Wormley, F. et al., “Resistance of T-Cell Receptor o-Chain-Deficient Mice to Experimental Candida Albicans Vaginitis,” Infection and Immunity, Nov. 2001, vol. 69, No. 11, pp. 7162-7164.
[cited by applicant]
Wilson et al., Biochimie 91 (2009) 1342-1345.
[cited by applicant]
Sigma-Aldrich in their Cook Book of Sep. 2010, vol. 12, Fundamental Techniques in Cell Culture Laboratory Handbook—2nd Edition, pp. 1-4.
[cited by applicant]
Bisset et al., Eur J. Haematol 2004: 72: 203-212.
[cited by applicant]
Groh et al., Nat Immunol Mar. 2001;2(3):255-60.
[cited by applicant]
Kowolik et al., Cancer Res 2006;66(22):10995-1004.
[cited by applicant]
Okamotoa et al., Cancer Res Nov. 10, 2009;69(23):9003-11.
[cited by applicant]
Yang et al., International Immunology 2007;19(9):1083-1093.
[cited by applicant]
Cooper et al., Blood Feb. 15, 2005;105(4):1622-31.
[cited by applicant]
Pardoll, Nat Biotechnol Dec. 2002;20(12):1207-8.
[cited by applicant]
Cooper et al., Cytotherapy 2006;8(2):105-117.
[cited by applicant]
Merriam-Webster dictionary definition for “isolated,” <http://www.merriam-webster.com/dictionary/isolated> downloaded Oct. 14, 2014, pp. 1-2.
[cited by applicant]
Pamela Stanley lab wiki, “Transfection of Cells with DNA,” <http://stanxterm.aecom.yu.edu/wiki/index.php?page=Transfection> Aug. 13, 2009, pp. 1-4.
[cited by applicant]
Schwab et al., J. of Imm. Sep. 1985;135(3):1714-8.
[cited by applicant]
Alegre et al., J. of Imm., Jun. 1992;148(11):3461-68.
[cited by applicant]
Bridgeman et al., J Immunol 2010;184:6938-6949.
[cited by applicant]
Barber et al., Experimental Hematology 2008;36:1318-1328.
[cited by applicant]
Schumacher, Nat Rev Immunol. Jul. 2002;2(7):512-9.
[cited by applicant]
Eagle et al., Curr Immunol Rev. Feb. 2009;5(1):22-34.
[cited by applicant]
Basu et al., Clinical Immunology 2008;129:325-332.
[cited by applicant]
Scheer et al., Methods Mol. Biol. Jul. 1, 2008;506:207-19.
[cited by applicant]
Llano et al., Methods Mol Biol. Jan. 1, 2008;485:257-70.
[cited by applicant]
Polic et al., PNAS Jul. 17, 2001;98(15):8744-9.
[cited by applicant]
Gascoigne et al., J. Biol. Chem. 1990;265:9296-9301.
[cited by applicant]
Rubin et al., Microscopy Research and Technique 2000;51:112-120.
[cited by applicant]
Chan SM, et al. “Single-cell analysis of siRNA-mediated gene silencing using multiparameter flow cytometry,” Cytometry A. Feb. 2006;69(2):59-65.
[cited by applicant]
Imai et al. “Genetic modification of T cells for cancer therapy,” J Biol Regul Homeost Agents. Jan.-Mar. 2004;18(1):62-71.
[cited by applicant]
Kambayashi T, et al. “IL-2 down-regulates the expression of TCR and TCR-associated surface molecules on CD8(+) T cells,” Eur J Immunol. Nov. 2001;31(11):3248-54.
[cited by applicant]
Okamoto S, et al. “Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR,” Cancer Res. Dec. 1, 2009;69(23):9003-11.
[cited by applicant]
Irving BA, et al. “The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways,” Cell. Mar. 8, 1991;64(5):891-901.
[cited by applicant]
Levin SD, et al. “A dominant-negative transgene defines a role for p56lck in thymopoiesis,” EMBO J. Apr. 1993;12(4):1671-80.
[cited by applicant]
Wu J, et al. “A functional T-cell receptor signaling pathway is required for p95vav activity,” Mol Cell Biol. Aug. 1995;15(8):4337-46.
[cited by applicant]
Ardouin L, et al. “Crippling of CD3-zeta ITAMs does not impair T cell receptor signaling,” Immunity. Apr. 1999;10(4):409-20.
[cited by applicant]
Lipowska-Bhalla G, et al. “Targeted immunotherapy of cancer with CAR T cells: achievements and challenges,” Cancer Immunol Immunother. Jul. 2012;61(7):953-62.
[cited by applicant]
Shores EW, et al. “Role of TCR zeta chain in T cell development and selection,” Science. Nov. 11, 1994;266(5187):1047-50.
[cited by applicant]
Shores EW, et al. “Role of the multiple T cell receptor (TCR)-zeta chain signaling motifs in selection of the T cell repertoire,” J Exp Med. Mar. 3, 1997;185(5):893-900.
[cited by applicant]
Wu AM, Tan GJ, Sherman MA, Clarke P, Olafsen T, Forman SJ, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. 2001;14(12):1025-33.
[cited by applicant]
Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.
[cited by applicant]
Yang OO, Nguyen PT, Kalams SA, Dorfman T, Gottlinger HG, Stewart S, et al. Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes. J Virol. 2002;76(4):1626-31.
[cited by applicant]
Yang OO, Tran A-C, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A. 1997;94(21):11478-83.
[cited by applicant]
Yang OO, Walker BD. CD8+ cells in human immunodeficiency virus type 1 pathogenesis: cytolytic and noncytolytic Inhibition of viral replication. Adv Immunol. 1997;66:273-311.
[cited by applicant]
Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trübel H, Pachman LM, Kitchingman GR, Campana D, Rohrer J, Conley ME. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. New England Journal of Med…
[cited by applicant]
Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans P. Targeting of T Lymphocytes to Melanoma Cells Through Chimeric Anti-GD3 Immunoglobulin T-Cell Receptors. Neoplasia. 2000;2(5):449-59.
[cited by applicant]
Zhu Y, Liu H, Wang Y, Wang B, Qian Q. Screening and Functional Research on Jurkat Cell Strain of Stable Chimeric Antigen Receptor Expression. Sci online. 2013. Retrieved from http://www.paper.edu.cn/download/downPaper/2…
[cited by applicant]
Zhu Y, Liu H, Wang Y, Wang B, Qian Q. Screening of Jurkat cells expressing FLT1-CAR and their chemotaxis to VEGF. Chinese J Cancer Biother. 2013;20(5):559-64.
[cited by applicant]
Pui CH, Relling MV, Sandlund JT, Campana D, Evans WE. Education Session 1: Treatment OF Acute Leukemia. Oct. 1999. Retrieved from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.622.3615&rep=rep1&type=pdf on S…
[cited by applicant]
Pule M, Finney HM, Lawson ADG. Artificial T-cell receptors. Cytotherapy. 2003;5(3):211-26.
[cited by applicant]
Quinn ER, Lum LG, Trevor KT. T cell activation modulates retrovirus-mediated gene expression. Hum Gene Ther. 1998;9(10):1457-67.
[cited by applicant]
Rabinovich PM, Komarovskaya ME, Ye ZJ, Imai C, Campana D, Bahceci E, Weissman SM. Synthetic messenger RNA as a tool for gene therapy. Human gene therapy. Oct. 1, 2006;17(10):1027-35.
[cited by applicant]
Regueiro JR, Martin-Fernández JM, Melero I. Immunity and gene therapy: benefits and risks. Inmunología. 2004;23(1):56-62.
[cited by applicant]
Riley JL, June CH. Genetically Modified T Cells for Human Gene Therapy. In: Dropulic B, Carter B, editors. Concepts in Genetic Medicine. Hoboken, New Jersey: John Wiley & Sons, Inc; 2008. p. 193-205.
[cited by applicant]
Roberts MR, Cooke KS, Tran A-C, Smith KA, Lin WY, Wang M, et al. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. J Immunol. 1998;161(1…
[cited by applicant]
Roberts MR, Qin L, Zhang DE, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Bl…
[cited by applicant]
Rondon IJ, Marasco WA. Gene Therapy for HIV-1 Using Intracellular Antibodies Against HIV-1 Gag Proteins. In: Marasco WA, editor. Intrabodies: Basic Research and Clinical Gene Therapy Applications. Springer Berlin Heidel…
[cited by applicant]
Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol. 1997;51:257-83.
[cited by applicant]
Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol. 2007;25(12):1444-54.
[cited by applicant]
Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99(6):2009-16.
[cited by applicant]
Rossig C, Brenner MK. Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol. 2003;110(2-3):154-9.
[cited by applicant]
Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10(1):5-18.
[cited by applicant]
Roszkowski JJ, Nishimura MI. Retroviral-Mediated Gene Transfer for Engineering Tumor-Reactive T-Cells. In: Disis ML, editor. Immunotherapy of Cancer. Humana Press; 2006. p. 213-33.
[cited by applicant]
Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive …
[cited by applicant]
Schirrmann T, Pecher G. Emerging Therapeutic Concepts III: Chimeric Immunoglobulin T Cell Receptors, T-Bodies. In: Dübel S, editor. Handbook of Therapeutic Antibodies. Weinheim, Germany: Wiley-VCH Verlag GmbH; 2008. p. …
[cited by applicant]
Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4(132):132ra53.
[cited by applicant]
Seow SV, Chai SMH, Tan PL, Yeoh AEJ, Campana D. Expansion and activation of allogeneic NK cells for adoptive Immunotherapy of advanced leukemia / lymphoma. In International Immunology Meeting Abstracts Aug. 1, 2010 (vol…
[cited by applicant]
Severino ME, Sarkis PTN, Walker BD, Yang OO. Chimeric immune receptor T cells bypass class I requirements and recognize multiple cell types relevant in HIV-1 infection. Virology. 2003;306(2):371-5.
[cited by applicant]
Shi J, Szmania S, Tricot G, Garg TK, Malaviarachchi PA, Moreno-Bost A, Stone K, Zhan F, Campana D, Shaughnessy J, Barlogie B. Activation and Expansion of Natural Killer (NK) Cells with Potent Cytotoxicity for Multiple M…
[cited by applicant]
Shibaguchi H, Luo NX, Kuroki M, Zhao J, Huang J, Hachimine K, et al. A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res. 2006;26(6 A):4067-72.
[cited by applicant]
Shimasaki N, Coustan-Smith E, Kamiya T, Campana D. Expanded and armed natural killer cells for cancer treatment. Cytotherapy. Nov. 30, 2016;18(11):1422-34.
[cited by applicant]
Sorg T, Methali M. Gene therapy for AIDS. Transfusion science. Jun. 30, 1997;18(2):277-89.
[cited by applicant]
Sprent J, Surh CD. T cell memory. Annual review of immunology. Apr. 2002;20(1):551-79.
[cited by applicant]
Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annual review of immunology. Apr. 2003;21(1):139-76.
[cited by applicant]
Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity. Dec. 19, 2008;29(6):848-62.
[cited by applicant]
Surh CD, Sprent J. Regulation of mature T cell homeostasis. In: Seminars in immunology Jun. 30, 2005 (vol. 17, No. 3, pp. 183-191). Academic Press.
[cited by applicant]
Szmania S, Garg TK, Lapteva N, Lingo JD, Greenway AD, Stone K, Woods E, Khan J, Stivers J, Nair B, Baxter-Lowe LA. Fresh ex vivo expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relaps…
[cited by applicant]
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S. Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo In High-Risk Relapsed Multiple My…
[cited by applicant]
Szmania S, Lapteva N, Garg TK, Lingo JD, Greenway AD, Bost A, Stone K, Khan J, Woods E, Nair B, Campana D. Expanded natural killer (NK) cells for immunotherapy: fresh and made to order. Blood. Nov. 16, 2012;120(21):1912.
[cited by applicant]
Takachi T, Iwabuchi H, Imamura M, Imai C. Lymphoblastic lymphoma with mature b-cell immunophenotype and MLL-AF9 in a child. Pediatric blood & cancer. Dec. 15, 2011;57(7):1251-2.
[cited by applicant]
Todisco E, Suzuki T, Srivannaboon K, Coustan-Smith E, Raimondi SC, Behm FG, Kitanaka A, Campana D. CD38 ligation inhibits normal and leukemic myelopoiesis. Blood. Jan. 15, 2000,95(2):535-42.
[cited by applicant]
Tsui L V, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, et al. Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol. 2002;20(1):53-7.
[cited by applicant]
Uherek C, Groner B, Wels W. Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J Hematother Stem Cell Res. 2001;10(4):523-34.
[cited by applicant]
Von Boehmer H, Kisielow P. Self-nonself discrimination by T cells. Science. Jun. 15, 1990;248(4961):1369-73.
[cited by applicant]
Von Laer D, Baum C, Protzer U. Antiviral gene therapy. In: Kräusslich H-G, Bartenschlager R, editors. Handbook of Experimental Pharmacology. Springer Berlin Heidelberg; 2009. p. 265-97.
[cited by applicant]
Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognitio…
[cited by applicant]
Walker BD. Immunotherapy with immune reconstitution and HIV. 2001;1-40. Retrieved from aids-chushi.or.jp on Oct. 13, 2016.
[cited by applicant]
Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467…
[cited by applicant]
Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a …
[cited by applicant]
Wang W, Erbe AK, Alderson KA, Phillips E, Gallenberger M, Gan J, Campana D, Hank JA, Sondel PM. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibi…
[cited by applicant]
Weijtens MEM, Hart EH, Bolhuis RLH. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 2000;7(1):35-42.
[cited by applicant]
Weijtens MEM, Willemsen RA, Hart EH, Bolhuis RLH. A retroviral vector system “Stitch” in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expres…
[cited by applicant]
Weijtens MEM. Immune-gene therapy for renal cancer chimeric receptor-mediated lysis of tumor cells. (Thesis.) Erasmus University Rotterdam; 2001.
[cited by applicant]
Wickremasinghe RG, Piga A, Campana D, Yaxley JC, Hoffbrand AV. Rapid down-regulation of protein kinase C and membrane association in phorbol ester-treated leukemia cells. FEBS letters. Oct. 7, 1985;190(1):50-4.
[cited by applicant]
Willcox N, Schluept M, Sommer N, Campana D, Janossy G, Brown AN, Newsom-Davist J. Variable corticosteroid sensitivity of thymic cortex and medullary peripheral-type lymphoid tissue in myasthenia gravis patients: structu…
[cited by applicant]
Willemsen RA, Debets R, Chames P, Bolhuis RLH. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol. 2003;64(1):56-68.
[cited by applicant]
Willemsen RA, Debets R, Hart EH, Hoogenboom HR, Bolhuis RLH, Chames P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gen…
[cited by applicant]
Wong Jr. KK, Chatterjee S. Adeno-associated virus based vectors as antivirals. In: Berns KI, Giraud C, editors. Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Springer-Verlag Berlin Heidelberg; 1996. p. 145-70.
[cited by applicant]
Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer research. Jan. 1, 2014;74(1):93-103.
[cited by applicant]
Kumagai MA, Coustan-Smith E, Murray DJ, Silvennoinen O, Murti KG, Evans WE, Malavasi F, Campana D. Ligation of CD38 suppresses human B lymphopoiesis. The Journal of experimental medicine. Mar. 1, 1995;181(3):1101-10.
[cited by applicant]
Labrecque N et al. How Much TCR Does a T Cell Need? Immunity. Jul. 2001;15(1):71-82.
[cited by applicant]
Lake DF, Salgaller ML, Van Der Bruggen P, Bernstein RM, Marchalonis JJ. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone di…
[cited by applicant]
Lamers CHJ, Willemsen RA, Luider BA, Debets R, Bolhuis RLH. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 2002;9(7):613-23.
[cited by applicant]
Lampson LA. Beyond inflammation: site-directed immunotherapy. Immunol Today. 1998;19(1):17-22.
[cited by applicant]
Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. …
[cited by applicant]
Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. In: Immunotherapy of Cancer: Methods and Protocols. Humana Press; 2010. p. 61-77.
[cited by applicant]
Leibman RS, Riley JL. Engineering T cells To Functionally Cure HIV-1 Infection. Mol Ther. 2015;23(7):1149-59.
[cited by applicant]
Leivas A, Pérez-Martínez A, Blanchard MJ, Clavero EM, Campana D, Lahuerta JJ, Martínez-López J. Autologous Activated and Expanded Natural Killer Cells are Safe and Clinically Actives in Multiple Myeloma. Blood. Dec. 3, …
[cited by applicant]
Leivas A, Pérez-Martínez A, Blanchard MJ, Clavero EM, Campana D, Lahuerta JJ, Martínez-López J. Multiple Infusions of Autologous Activated and Expanded Natural Killer Cells: A New Therapeutic Option for Multiple Myeloma…
[cited by applicant]
Leivas A, Risueño RM, Pérez-Martínez A, Campana D, Lahuerta JJ, Martínez-López J. Autologous Activated and Expanded Natural Killer Cells Destroy Multiple Myeloma Clonogenic Tumor Cells through NKG2D and Its Ligands. Cli…
[cited by applicant]
Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C. High success rate of hematopoietic cell transplantation regardless of donor source in children wi…
[cited by applicant]
Li L, Wolfraim L, Allen C, Viley A, Fujisaki H, Campana D, Fratantoni JC, Peshwa MV. A Highly Efficient, Clinically Applicable Transfection Method to Redirect the Specificity of Immune Cells and Enhance Their Anti-Tumor…
[cited by applicant]
Liao KW, Chou WC, Lo YC, Roffler SR. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng. 2001;73(4):313-23.
[cited by applicant]
Lim KS, Kua LF, Mimura K, Shiraishi K, Chng WJ, Yong WP, Campana D, Kono K. Implication of highly cytotoxic natural killer cells for esophageal cancer treatment. Cancer Research. Aug. 1, 2015;75(15 Supplement):3148.
[cited by applicant]
Liu C, Ma X, Liu B, Chen C, Zhang H. HIV-1 functional cure: will the dream come true? BMC Med. 2015;13(1):284.
[cited by applicant]
Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, et al. Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol. 2015;89(13…
[cited by applicant]
Lund JA, Spach DH, Collier AC. Future Anti-HIV Therapy. In: Spach DH, Hooton TM, editors. The HIV Manual: A Guide to Diagnosis and Treatment. Oxford University Press; 1996. p. 89-104.
[cited by applicant]
Lund O, Lund OS, Gram G, Nielsen SD, Schønning K, Nielsen JO, et al. Gene therapy of T helper cells in HIV Infection: mathematical model of the criteria for clinical effect. Bull Math Biol. 1997;59(4):725-45.
[cited by applicant]
Luszczek W, Morales-Tirado V, van der Merwe M, Kudo K, Campana D, Pillai A. Expanded human regulatory iNKT cells exhibit direct cytotoxicity against hematolymphoid tumor targets. Cancer Research. Apr. 15, 2012;72(8 Supp…
[cited by applicant]
Ma Q, Gonzalo-Daganzo RM, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. Cancer Chemother Biol Response Modif. 2002;20:315-41.
[cited by applicant]
Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP. Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate. 2004;61(1):12-25.
[cited by applicant]
Marathe JG, Wooley DP. Is gene therapy a good therapeutic approach for HIV-positive patients? Genet Vaccines Ther. 2007;5:5.
[cited by applicant]
Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, D'Amico G. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-ζ, activating signal…
[cited by applicant]
Martinius HO. Präklinische Untersuchungen zur Gentherapie der HIV-Infektion mit dem retroviralen Vektor M87o (Preclinical examinations on genetherapy of HIV infection with the retroviral vector M870). (Thesis.) Goethe U…
[cited by applicant]
Masiero S, Del Vecchio C, Gavioli R, Mattiuzzo G, Cusi MG, Micheli L, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005;12:299-310.
[cited by applicant]
McGuinness RP, Ge Y, Patel SD, Kashmiri SVS, Lee H-S, Hand PH, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther. 1999;10(2):165-73.
[cited by applicant]
Mihara K, Imai C, Coustan-Smith E, Dome JS, Dominici M, Vanin E, Campana D. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. British j…
[cited by applicant]
Mihara K, Yanagihara K, Imai C, Kimura A, Campana D. Development of Effective Immunotherapy for B-Cell Non-Hodgkin's Lymphoma with CD19-Specific Cytotoxic T Cells. Blood. Nov. 16, 2004;104(11):3277.
[cited by applicant]
Mihara K, Yanagihara K, Takigahira M, Imai C, Kitanaka A, Takihara Y, Kimura A. Activated T-cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma. Journal of Immunotherapy. Sep…
[cited by applicant]
Mihara K, Yanaghara K, Takgahra M, Ktanaka A, Imai C, Bhattacharyya J, Kubo T, Takei Y, Yasunaga SI, Takhara Y, Kimura A. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric re…
[cited by applicant]
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of…
[cited by applicant]
Mimura K, Kamiya T, Shiraishi K, Kua LF, Shabbir A, So J, Yong WP, Suzuki Y, Yoshimoto Y, Nakano T, Fujii H. Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. International Journal of Ca…
[cited by applicant]
Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S. Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensi…
[cited by applicant]
Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immu…
[cited by applicant]
Muniappan A, Banapour B, Lebkowski J, Talib S. Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 2000;7(1):128-34.
[cited by applicant]
Nešić D, Vukmanović S. MHC class I is required for peripheral accumulation of CD8+ thymic emigrants. The Journal of Immunology. Apr. 15, 1998;160(8):3705-12.
[cited by applicant]
Nguyen PT, Duthoit CT, Geiger TL. Induction of tolerance and immunity by redirected B cell-specific cytolytic T lymphocytes. Gene Ther. 2007;14(24):1739-49.
[cited by applicant]
Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD47 by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV…
[cited by applicant]
Palù G, Li Pira G, Gennari F, Fenoglio D, Parolin C, Manca F. Genetically modified immunocompetent cells in HIV infection. Gene Ther. 2001;8(21):1593-600.
[cited by applicant]
Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG. Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther. 1999;6(3):412-9.
[cited by applicant]